AbCellera Biologics Inc. (ABCL) News
Filter ABCL News Items
ABCL News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
ABCL News Highlights
- ABCL's 30 day story count now stands at 14.
- Over the past 28 days, the trend for ABCL's stories per day has been choppy and unclear. It has oscillated between 1 and 7.
- DECK are the most mentioned tickers in articles about ABCL.
Latest ABCL News From Around the Web
Below are the latest news stories about AbCellera Biologics Inc that investors may wish to consider to help them evaluate ABCL as an investment opportunity.
AbCellera Biologics Inc. 2021 Q4 - Results - Earnings Call PresentationThe following slide deck was published by AbCellera Biologics Inc. in conjunction with their 2021 Q4 earnings call.... |
AbCellera Biologics GAAP EPS of $0.19 beats by $0.01, revenue of $139.3M beats by $17.44MAbCellera Biologics press release (ABCL): Q4 GAAP EPS of $0.19 beats by $0.01.Revenue of $139.3M beats by $17.44M.“In 2021 we made significant advancements in executing our… |
AbCellera Reports Full Year 2021 Business ResultsVANCOUVER, British Columbia, February 24, 2022--AbCellera Reports Full Year 2021 Business Results |
AbCellera Biologics Q4 2021 Earnings PreviewAbCellera Biologics (NASDAQ:ABCL) is scheduled to announce Q4 earnings results on Thursday, February 24th, after market close.The consensus EPS Estimate is $0.17 and the consensus… |
AbCellera to Participate Virtually in the Truist Securities AI Symposium – Biotech & ToolsVANCOUVER, British Columbia, February 23, 2022--AbCellera to Participate Virtually in the Truist Securities AI Symposium – Biotech & Tools |
AbCellera Biologics: Bebtelovimab Supply Deal Provides A Much Needed Shot In The ArmNo summary available. |
AbCellera-Discovered Antibody, Bebtelovimab, Receives U.S. FDA Emergency Use Authorization for the Treatment of Mild-to-Moderate COVID-19VANCOUVER, British Columbia, February 11, 2022--AbCellera-Discovered Antibody, Bebtelovimab, Receives U.S. FDA Emergency Use Authorization for the Treatment of Mild to Moderate COVID-19 |
AbCellera to Present Virtually at the 11th Annual SVB Leerink Global Healthcare Conference on February 17, 2022VANCOUVER, British Columbia, February 11, 2022--AbCellera to Present Virtually at the 11th Annual SVB Leerink Global Healthcare Conference on February 17, 2022 |
Lilly to Supply up to 600,000 Doses of AbCellera-Discovered Antibody, Bebtelovimab, to the U.S. Government in Ongoing Effort to Provide COVID-19 TreatmentsVANCOUVER, British Columbia, February 11, 2022--Lilly to Supply up to 600,000 Doses of AbCellera-Discovered Bebtelovimab to the U.S. Government in Ongoing Effort to Provide COVID-19 Treatments |
AbCellera to Report Full Year 2021 Financial Results on February 24, 2022VANCOUVER, British Columbia, January 27, 2022--AbCellera to Report Full Year 2021 Financial Results on February 24, 2022 |